Diabetes mellitus is characterized by oxidative stress, which in turn determines endothelial dysfunction. Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring. It has been reported to potentially protect the vasculature through improvements in plasma lipid levels and platelet function. We hypothesized that gliclazide has a beneficial effect on endothelial function in Goto-Kakizaki rats (GK), an animal model of type 2 diabetes fed an atherogenic diet for 4 months. We evaluated the influence of gliclazide on both metabolic and oxidative status and NO-mediated vasodilation. GKAD rats showed increased oxidative stress and impaired endothelium-dependent vasodilation. GKAD rats treated with gliclazide showed increased sensitivity to NO-mediated vasodilation, a significant decrease in fasting glycemia and insulinemia, and a significant decrease in systemic oxidative stress. In conclusion, our results suggest that gliclazide treatment improves NO-mediated vasodilation in diabetic GK rats with dyslipidemia probably due to its antioxidant effects, although we cannot rule out substantial benefits due to a reduction in fasting blood glucose. The availability of a compound that simultaneously decreases hyperglycemia, hyperinsulinemia, and inhibits oxidative stress is a promising therapeutic candidate for the prevention of vascular complications of diabetes.

Institute of Physiology University of Coimbra Coimbra

Lit.: 27

000      

00000naa 2200000 a 4500

001      

bmc07530687

003      

CZ-PrNML

005      

20111210151749.0

008      

091009s2009 xr e eng||

009      

AR

024    7_

$a 10.33549/physiolres.931480 $2 doi

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Sena, S. M.

245    10

$a Antioxidant and vascular effects of gliclazide in type 2 diabetic rats fed high-at diet / $c C. M. Sena, T. Louro, P. Matafome, E. Nunes, P. Monteiro, R. Seiça

314    __

$a Institute of Physiology, University of Coimbra, Coimbra

504    __

$a Lit.: 27

520    9_

$a Diabetes mellitus is characterized by oxidative stress, which in turn determines endothelial dysfunction. Gliclazide is a sulphonylurea antidiabetic drug with antioxidant effects due to its azabicyclo-octyl ring. It has been reported to potentially protect the vasculature through improvements in plasma lipid levels and platelet function. We hypothesized that gliclazide has a beneficial effect on endothelial function in Goto-Kakizaki rats (GK), an animal model of type 2 diabetes fed an atherogenic diet for 4 months. We evaluated the influence of gliclazide on both metabolic and oxidative status and NO-mediated vasodilation. GKAD rats showed increased oxidative stress and impaired endothelium-dependent vasodilation. GKAD rats treated with gliclazide showed increased sensitivity to NO-mediated vasodilation, a significant decrease in fasting glycemia and insulinemia, and a significant decrease in systemic oxidative stress. In conclusion, our results suggest that gliclazide treatment improves NO-mediated vasodilation in diabetic GK rats with dyslipidemia probably due to its antioxidant effects, although we cannot rule out substantial benefits due to a reduction in fasting blood glucose. The availability of a compound that simultaneously decreases hyperglycemia, hyperinsulinemia, and inhibits oxidative stress is a promising therapeutic candidate for the prevention of vascular complications of diabetes.

650    _2

$a financování organizované $7 D005381

650    _2

$a acetylcholin $x farmakologie $7 D000109

650    _2

$a zvířata $7 D000818

650    _2

$a antioxidancia $x farmakologie $7 D000975

650    _2

$a tělesná hmotnost $7 D001835

650    _2

$a deoxyguanosin $x analogy a deriváty $x moč $7 D003849

650    _2

$a diabetes mellitus 2. typu $x farmakoterapie $x komplikace $x metabolismus $7 D003924

650    _2

$a diabetické angiopatie $x metabolismus $x prevence a kontrola $7 D003925

650    _2

$a dietní tuky $x farmakologie $7 D004041

650    _2

$a modely nemocí na zvířatech $7 D004195

650    _2

$a dyslipidemie $x komplikace $x metabolismus $7 D050171

650    _2

$a gliklazid $x farmakologie $7 D005907

650    _2

$a hypoglykemika $x farmakologie $7 D007004

650    _2

$a oxid dusnatý $x metabolismus $7 D009569

650    _2

$a oxidační stres $x účinky léků $7 D018384

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a mutantní kmeny potkanů $7 D011922

650    _2

$a potkani Wistar $7 D017208

650    _2

$a vazodilatace $x účinky léků $7 D014664

650    _2

$a vazodilatancia $x farmakologie $7 D014665

700    1_

$a Louro, T.

700    1_

$a Matafome, P.

700    1_

$a Nunes, E.

700    1_

$a Monteiro, P.

700    1_

$a Seiça, R.

773    0_

$w MED00003824 $t Physiological research $g Roč. 58, č. 2 (2009), s. 203-209 $x 0862-8408

856    41

$u http://www.biomed.cas.cz/physiolres/pdf/58/58_203.pdf $y plný text volně přístupný

910    __

$a ABA008 $b A 4120 $c 266 $y 9

990    __

$a 20091009100046 $b ABA008

991    __

$a 20091009125703 $b ABA008

999    __

$a ok $b bmc $g 689213 $s 551054

BAS    __

$a 3

BMC    __

$a 2009 $b 58 $c 2 $d 203-209 $i 0862-8408 $m Physiological research $x MED00003824

LZP    __

$a 2009-32/mkme